Veracyte (VCYT) vs. Its Peers Financial Analysis
Veracyte (NASDAQ: VCYT) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its rivals? We will compare Veracyte to similar companies based on the strength of its risk, dividends, analyst recommendations, earnings, profitability, institutional ownership and valuation.
This table compares Veracyte and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Veracyte and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Veracyte currently has a consensus price target of $11.08, suggesting a potential upside of 91.36%. As a group, “Medical laboratories” companies have a potential upside of 14.00%. Given Veracyte’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Veracyte is more favorable than its rivals.
Valuation and Earnings
This table compares Veracyte and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Veracyte||$71.95 million||-$31.00 million||-6.36|
|Veracyte Competitors||$1.13 billion||$76.65 million||217.38|
Veracyte’s rivals have higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
70.5% of Veracyte shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are owned by institutional investors. 13.4% of Veracyte shares are owned by insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Veracyte has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Veracyte’s rivals have a beta of 1.23, meaning that their average stock price is 23% more volatile than the S&P 500.
Veracyte beats its rivals on 8 of the 12 factors compared.
Veracyte Company Profile
Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional managers, account managers, and medical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.